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Aim: To study the efficiency of multifunctional polymer-based superparamagnetic iron oxide nanoparticles
(bioferrofluids) as a T2 magnetic resonance contrast agent and their uptake and toxicity in liver. Materials
& methods: Mice were intravenously injected with bioferrofluids and Endorem R©. The magnetic resonance
efficiency, uptake and in vivo toxicity were investigated by means of magnetic resonance imaging (MRI)
and histological techniques. Results: Bioferrofluids are a good T2 contrast agent with a higher r2/r1
ratio than Endorem. Bioferrofluids have a shorter blood circulation time and persist in liver for longer
time period compared with Endorem. Both bioferrofluids and Endorem do not generate any noticeable
histological lesions in liver over a period of 60 days post-injection. Conclusion: Our bioferrofluids are
powerful diagnostic tool without any observed toxicity over a period of 60 days post-injection.
Lay abstract: Several superparamagnetic iron oxide nanoparticles (SPIONs) preparations have been ap-
proved by US FDA for clinical use as MRI contrast agents. In recent years, we have been developing a
synthetic multifunctional platform for SPIONs based on the use of polymers. In this report, we explored
the diagnostic potential of these nanoparticles (herein called bioferrofluids) as an MRI contrast agent and
their uptake in liver, without neglecting their toxicological effects. Results show that our bioferrofluids
are a good T2 contrast agent without any observed toxicity in liver.
First draft submitted: 20 April 2017; Accepted for publication: 28 June 2017; Published online: 18 Septem-
ber 2017
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Introduction
Over the past few decades biological applications of nanomaterials have become a subject of intense research
activity [1]. This has been particularly so since around the beginning of this century in the case of superparamagnetic
iron oxide nanoparticles (SPIONs) [2]. Particles of about 20 nm or less have unique properties that adjust very well
to functionalities of interest in biomedical applications. Besides their size being comparable to many biological
objects, their magnetic behavior is superparamagnetic, so they can be easily magnetized in the presence of an external
magnetic field, their magnetization coming to zero as soon as the field is suppressed [3]. Their magnetization values
are orders of higher magnitude compared with the values corresponding to transition metal or lanthanide ions,
so they can strongly affect the spin–spin relaxation times (T2) of nearby water protons. This makes magnetic
nanoparticles (MNPs) excellent contrast agents (CAs) in MRI [3–5]. Their strong magnetization also allows them to
be fixed, moved, tagged or detected magnetically thus making them useful in bioseparation, diagnosis or in targeted
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Figure 1. Schematic representation of multicore magnetic nanoparticles with their polymeric multifunctional
coating.
drug delivery [6,7]. Moreover, they can also respond resonantly to an alternating magnetic field and induce heating,
therefore being of interest for magnetic-induced hyperthermia [8–10].
MRI is considered one of the most promising non-invasive diagnostic tool in medical science since it provides
3D anatomical images with high spatial resolution in the submillimeter range and high soft tissue contrast [11].
Several SPION preparations have been approved by US FDA for clinical use as magnetic resonance (MR) CAs,
such as EndoremR© for liver imaging [12].
The successful biomedical application of a nanomaterial is a reflection of its adequate design. Several factors
should be taken into account such as size [13–15], shape [16], surface charge [17] and surface modification [18], to list
but a few. Regarding surface modification (e.g., coating [13]), coating the nanomaterial with a polymeric coating
reduces protein adsorption to nanomaterial surface and subsequently can reduce the nanomaterial clearance from
the circulation through opsonization process. The most commonly used polymer is polyethylene glycol (PEG),
since it is inexpensive, versatile and is currently listed as ‘generally recognized as safe’ by the FDA. Addition of PEG
to the nanomaterial surface (PEGylation) increases the blood circulation time and reduces the non-specific binding
of proteins, depending on the chain length of PEG. Chain lengths of about 2 kDa molecular weight are considered
very suitable for this purpose, although much longer chains have also been proposed [19–22].
In the recent years we have been developing a synthetic multifunctional platform for SPIONs based on the use
of polymers [23,24]. They consist of:
 Maghemite (γ-Fe2O3) cores that are embedded in
 A hydrophobic, poly(4-vinyl pyridine) (P4VP) matrix, covered by
 A shell of a second hydrophilic polymer, PEG, that confers to the material high solubility, stability in aqueous
solutions and biocompatibility, and
 Other physical functionalities such as fluorescent dyes.
Part of the PEG chains are functionalized with –COOH groups to provide sites for the anchoring of antibodies or
other biological substances to the nanoparticle surface, so they can be directed to specific targets. The nanoparticle
core consists of a small number of maghemite MNPs, for which diameters can be varied from 4 to 25 nm,
all embedded within the P4VP matrix, thus preventing agglomeration, and then coated with PEG. The final
hydrodynamic diameter of the nanoparticle including core and polymeric coatings can be varied from 50 to
160 nm. Altogether, the system consists of multicore nanobeads (Figure 1) that can be dispersed in phosphate-
buffered saline (PBS), thus resulting in a magnetic fluid stable at pH = 7.4 and human body temperature that in
the following will be designated as bioferrofluid [24].
In vitro cytotoxicity studies of these nanoparticles showed little incidence of oxidative stress, and inflammasome
activation was only observed with the smaller nanoparticles at high concentration [25].
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The hemostatic behavior of these bioferrofluids indicates no significant change in the complete blood counts and
absence of hemolysis. Coagulation studies indicate that these bioferrofluids behave as non-specific anticoagulant, as
lengthening of the activated partial thromboplastin time was detected, the degree of activated partial thromboplastin
time lengthening being comparable to that of heparin and well within therapeutic range [26].
Stable colloidal suspensions of these nanoparticles have shown excellent relaxometric and magnetothermic
responses compared with Endorem [27,10].
Altogether these studies make these bioferrofluids as good candidates for theranostics.
The purpose of this work is to investigate the MR efficiency of such polymeric-coated multicore nanoparticles as
a T2 MR CA and their uptake and toxicity in mice using MRI and histological techniques. Studies concentrate on
liver; uptake and toxicity effects in other organs are in preparation and will be published elsewhere. The results will
be contrasted with those obtained using commercialized Endorem magnetic fluids following the same experimental
conditions.
Materials & methods
Bioferrofluids preparation & characterization
The synthesis of bioferrofluids was performed using co-precipitation method through a polymeric route. The
synthesis was carried out in two steps: synthesis ofmaghemite/P4VP nanocomposite and formation of bioferrofluids
by dispersion of the nanocomposite in acidic pH and coating with a hydrophilic polymer (PEG acrylate [PEGA]).
Two types of PEGA chains were used, one of them with 200 Da molecular weight [PEGA(200)] and hydroxyl
terminal groups, and the other with 1000 Da molecular weight and carboxyl terminal groups [PEGA(1000)-COO]
that can be used for further functionalization. The polymers were added in a 9:1 ratio per weight, respectively,
and were allowed to react with the P4VP by Michael addition reaction. The pH of the suspension was adjusted
to 7.4 and the ionic strength to 0.15 M. The prepared bioferrofluids were finally filter-sterilized using a 0.22 μm
nitrocellulose filter.
The total iron content in the samples was determined by atomic emission in a plasma 40 inductively coupled
plasma Perkin–Elmer spectrometer. The size of the maghemite nanoparticles was determined from transmission
electronmicroscopy (TEM) images while the hydrodynamic size distribution of the P4VP-g-PEGA-coated nanopar-
ticles was determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS fromMalvern (Worcestershire,
UK).
A detailed description of bioferrofluids preparation and characterization is provided in previous publica-
tions [24,26].
In vitro relaxation measurement
In vitro MR imaging was performed with a Biospec Tomograph system (Bruker Medical systems, Karlsruhe,
Germany) operating at 200 MHz (4.7 T) and equipped with a 33-cm bore magnet (Oxford Ltd, UK). The system
was operating using Paravision 5.1 software (Bruker, Karlsruhe, Germany). Samples were prepared in physiological
saline solutions at different concentrations of bioferrofluids and Endorem, then inserted in a 7.2 cm internal
diameter (i.d) birdcage coil. Transverse (T2) and longitudinal (T1) relaxation times were measured. Measurement
parameters are provided in the supplementary material section.
Longitudinal and transversal relaxation rates (1/T1, s-1 and 1/T2, s-1, respectively) were plotted as a function of
iron concentration, expressed in mM of iron, and longitudinal (r1) and transverse (r2) relaxivities were obtained by
the slope of the fitting straight line.
In vivo perfusion MRI
A total number of five, 6-7 weeks old, male BALB/c mice weighting 19-22 g were used. Mice were purchased from
Harlan Laboratories (Udine, Italy) and housed with free access to water and food, under controlled environmental
parameters and veterinary control in the animal facility of the University of Verona.
Mice were pre-anesthetized and intravenously injected via the tail vein with aqueous suspensions of either
bioferrofluid or EndoremR© at a dose of 23.5 mg Fe/kg body weight.
First-passage images were acquired using an echo-planar imaging sequence. Images were acquired during 60
s following the injection. The obtained signal intensity (SI) values were normalized according to the following
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−
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where SI (t) is the SI at time t, SI (0) is the SI before injection.
In order to evaluate the performance of the bioferrofluid as a CA compared with Endorem, experiments mapping
the cerebral blood flow (CBF) and cerebral blood volume (CBV) bolus tracking (first passage) were performed [28].
Regional CBV (rCBV) can also be measured using blood pool CAs, at the steady-state concentration of CA in
blood, by acquiring T2* images before and after CA injection and using the following relationship [29]:
rCBV K SI pre
SI post
= × ln ( )
( ) (2)
where, K is a constant depending on instrumental parameters; SI (pre) and SI (post) are brain SI values before and
after CA injection, respectively.
Steady-state images were acquired before and during 2 h after injection of CA using a gradient echo sequence.
A detailed description of the methodology with the measurement parameters are provided in the supplementary
material section.
Liver MRI study
Mice were intravenously injected via the tail vein with aqueous suspensions of either bioferrofluids or Endorem at
a dose of 20 μmol Fe/kg body weight. Images for the whole body were taken before injection (pre) and at different
time points after injection (5 min–2 h, 24 h and 7, 15, 30 and 60 days). Quantitative T2 maps and T2*-weighted
images were acquired using the parameters indicated in the supplementary material section.
In vivo toxicity & qualitative iron detection studies
At each time point (2 h, 24 h and 7, 15, 30 and 60 days), animals were sacrificed through cervical dislocation;
dissected tissues were processed for toxicity studies and qualitative iron detection using Prussian blue assay.
Methodologies are described in details in the supplementary material section.
Statistical analysis
Obtained data were presented in the curves as (mean± SEM), the number of readings at each time point is indicated
by symbol (n), data were analyzed using Mann–Whitney test. p < 0.05 was considered statistically significant.
Results
Bioferrofluids characterization
Bioferrofluids were characterized by TEM and DLS and the results are shown in Figure 2. TEM images show that
the polymer coating did not give an appreciable contrast against the carbon film of the sample holder; thus, only
the maghemite MNPs were visible. Figure 2A shows TEM images of several multicore nucleus with sizes of several
tenths of nanometers. The individual maghemite MNPs in the nucleus are rounded and their average size from
the analysis of TEM images was 13.08 ± 2.33 nm (Mean ± SD) (Figure 2B). DLS observations show a single
population of nanoparticles with an average hydrodynamic diameter of 163 nm (Figure 2C). The Fe2O3 content
of the bioferrofluids stock solution was 8.1 g/l.
A well-known MRI CA, Endorem, (Guerbet, Villepinte, France), was used in this work as a reference material.
Endorem is composed of magnetite nanoparticles with a size range between 6 and 9 nm, coated with a polymeric
dextran. The hydrodynamic diameter of Endorem is ranging between 80 and 150 nm. Measurement of the
hydrodynamic diameter in our laboratory yields an average of hydrodynamic diameter of 110 nm. The Endorem
concentration is 11.2 g/l Fe.
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Figure 2. Bioferrofluids characterization. (A) TEM images of maghemite MNPs in the bioferrofluid; (B) size distribution of spherical
maghemite MNPs; (C) DLS size distribution of hydrodynamic size in the bioferrofluids sample.
DLS: Dynamic light scattering; MNPs: Magnetic nanoparticles; TEM: Transmission electron microscopy.
In vitro relaxation measurement
T2 and T1 relaxation times were measured for both, Endorem and bioferrofluids. It was evident that these biofer-
rofluids exhibit the typical property of SPIONs of shortening T2 relaxation time, as increasing the nanoparticles
concentration is associated with a decrease in SI, as shown in Supplementary Figure 1. Obtained values of trans-
verse and longitudinal relaxation rates of bioferrofluids and Endorem have been plotted as a function of the iron
concentration in mM in Figure 3. Both 1/T2 and 1/T1 relaxation rates are linearly proportional to the iron
concentration as shown in Figure 3A & B. Relaxivity coefficient values (r2 and r1 ± C.I.) were obtained from
the slope of the fitting straight lines. r2 values are 113.99 ± 11.08 and 82.8 ± 8.28 mM-1s-1, while r1 values are
2.11 ± 0.21 and 0.45 ± 0.05 mM-1s-1 for Endorem and bioferrofluids, respectively. It is worthwhile to mention
that, at high iron concentration, the trend of 1/T2 for bioferrofluids slightly deviates from linearity and conse-
quently r2 for bioferrofluids may be underestimated. Indeed, if we assume that this deviation can be attributed
to experimental artifacts and eliminate the last two points, the calculated transversal relaxivity for bioferrofluids
future science group 10.4155/fsoa-2017-0054
Research Article Ali LMA, Marzola P, Nicolato E et al.
0
20
40
60
80
100
120
140
1/
T
2 
(S
-1
)
0.0 0.2 0.4 0.6 0.8 1.0 1.2
[Fe] mM
r2 = 113.99 ± 11.08 mM
-1s-1
r2 = 82.80 ± 8.28 mM
-1s-1
1/T2 endorem®
1/T2 bioferrofluids
0.0 0.2 0.4 0.6 0.8 1.0 1.2
[Fe] mM
0.0
0.5
1.0
1.5
2.0
2.5
3.0
1/
T
1 
(S
-1
)
1/T1 endorem®
1/T1 bioferrofluids
r1 = 2.11 ± 0.21 mM
-1s-1
r1 = 0.45 ± 0.05 mM
-1s-1
Figure 3. In vitro relaxation measurement. Comparative analysis of the transverse relaxation rates (1/T2, s-1) (A) and longitudinal
relaxation rates (1/T1, s-1) (B) of bioferrofluids and Endorem
R© as a function of iron concentration (mM). r2 and r1 were calculated from
the slopes of each plot.
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Figure 4. A dynamic first-passage bolus tracking curve for both Endorem R© and bioferrofluids during an acquisition
time of 60 s.
amounts to 104.7 ± 9.7 mM-1s-1, not statistically different from values reported for Endorem in the present and
in other studies [30]. These results indicate that bioferrofluids have transversal relaxivity lower than Endorem or, at
most, comparable. Transversal to longitudinal relativity values (r2/r1 ratios) were 54.02 and 184 for Endorem and
bioferrofluids, respectively.
In vivo perfusion MRI
A dynamic first-passage bolus tracking method was used in order to assess the usefulness of investigated CA in
cerebral perfusion experiments. A first-passage CA curve, plotting the enhancement (%) versus the time point after
injection is shown in Figure 4. These results clarify the effect of both Endorem and bioferrofluids on SI in vivo. Both
cause a decrease in SI values with a different degree. SI decreases more with Endorem than with the bioferrofluids.
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Figure 5. In vivo perfusion MRI. T2*-weighted images for a mouse brain vasculature before (A, E), 5 min (B, F) and
2 h (C, G) after injection of Endorem R© (upper panel) and bioferrofluids (lower panel). rCBV maps for Endorem and
bioferrofluids are shown in (D) and (H), respectively.
rCBV: Regional cerebral blood volume
To evaluate the performance of the bioferrofluid as a CA compared with Endorem in steady-state condition,
T2*-weighted images in brain were acquired before (pre) and during 2 h after (post) injection of Endorem and
bioferrofluids at a dose of 23.5 mg Fe/kg body weight. Before injection, the brain vasculature appeared clear
(Figure 5A & E). Few minutes after injection of Endorem and bioferrofluids, a decrease in SI was observed for
both CAs (Figure 5B & F), which is indicated by a darkening in the brain vasculature (hypointense) emphasizing
the existence of the CAs in the circulation. Two hours after injection, a hypointense brain vasculature was observed
for the mouse injected with Endorem (Figure 5C); however, a cleared brain vasculature was observed for the
mouse injected with bioferrofluids that emphasizes the clearance of bioferrofluids from the circulation (Figure 5G).
Figure 5D & H shows rCBV maps calculated pixel-by-pixel according to Equation (2) with Endorem and
bioferrofluids, respectively.
For a quantitative data analysis, SI values in T2*-weighted images were obtained by identifying the region of
interest (ROIs) in the brain. These values were normalized to SI of the standard, and then the SI ratio (R) was
calculated according to the following equation:
R SI post /SI Pre= ( ) ( ) (3)
where, SI (post) is the SI after injection and SI (pre) is the SI before injection.
These data are plotted in Supplementary Figure 2 as a function of the acquisition time. It is evident that both
CAs attenuate SI inside the brain in few minutes after injection, since R values were 0.51 ± 0.11 and 0.67 ± 0.16
(mean ± SD) compared with pre-injection values 1.00 ± 0.14 and 1.00 ± 0.18 for Endorem and bioferrofluids,
respectively. With increasing time, a small increase in R was observed for Endorem. However, R observed for
bioferrofluids shows a more pronounced increase, as is after 2 h it returns to the pre-injection value. Since CAs
remain confined in the vascular space in normal brain, the drop in SI is attributable to iron contained in blood
vessels, and consequently, the recovery of the parameter R to its pre-contrast value indicates, within the limit of the
sensitivity of MRI, complete clearance of the bioferrofluids from the circulation. Supplementary Figure 2 indicates
that bioferrofluids have cleared faster (i.e., have a shorter half-life time in blood) than Endorem.
Liver MRI study
SI values in T2*-weighted images, as well as quantitative T2 values were obtained by identifying ROIs in liver. T2
values were obtained by fitting the theoretical dependence of SI on the echo time for the multi-echo acquisition
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Figure 6. Liver MRI study. Transverse relaxation time values (A) and signal intensity ratio values (B) of bioferrofluids
and Endorem R© in liver during 2 h after contrast agent injection. Data are presented as (mean ± SEM).
*Marks significant differences between Endorem and bioferrofluids, according to Mann–Whitney test, n = 10.
sequence to experimental data.
SI T SI e CE
TE/T( ) ( ) [ ] 0 2 (4)
where, SI(TE) is the SI at certain echo time, SI(0) is the signal at zero time, TE is the echo time, T2 is the transverse
relaxation time and C is a constant. The fitting was performed pixel-by-pixel by using the image sequence analysis
(ISA) tool of Paravision 5.1 software.
SI values in T2*-weighted images were normalized to SI of brain, which was not significantly different from the
pre-injection value at the used dosage, and then R was calculated according to Equation (3).
Before injection, T2 values in the liver were 39.27 ± 2.98 (mean ± SD) and 40.30 ± 1.46 ms in the
bioferrofluid and Endorem groups, respectively. Few minutes after CA injection, a decrease was detected in T2
values, 33.11 ± 2.93 and 29.11 ± 1.47 ms for bioferrofluids and Endorem injected mice groups, respectively, as
represented in Figure 6A. These results are compatible with R results shown in Figure 6B, as a decrease in R values
was also observed. The darkening in the liver tissue due to CA accumulation after 2 h of injection is shown in
Supplementary Figure 3.
10.4155/fsoa-2017-0054 Future Sci. OA (2017) FSO235 future science group
Polymer-coated superparamagnetic iron oxide nanoparticles as T2 contrast agent for MRI and their uptake in liver Research Article
27
29
31
33
35
37
39
41
43
-10 10 30 50 70
Time (days)
T
2 
(m
s)
*
*
*
Bioferrofluids
Endorem®
Figure 7. Transverse relaxation time values of
bioferrofluids and Endorem R© in liver during 60 days
after contrast agent injection.
Data are presented as (mean ± SEM).
*Marks significant differences between Endorem and
bioferrofluids, according to Mann–Whitney test, (until
15 days: n = 10; at 30 days: n = 8; and at 60 days: n = 4).
Estimation for the iron concentration in liver could be obtained from the following equation:
1 1 02 2 2/T t /T r C( ) ( )= + (5)
where, 1/T2(t) (in s-1) is the transverse relaxation rate of a system after CA administration, 1/T2(0) (in s-1) is the
transverse relaxation rate of a system before CA administration, r2 (in mM-1S-1) is the relaxivity of the CA in the
desired system and C is the concentration (in mM).
By using the experimentally determined T2 values for the liver in both bioferrofluids and Endorem after 2 h of
injection and the r2 relaxivity (measured in physiological saline solution) we could estimate an iron concentration
of about 0.05 μM in both cases.
T2 and T2*-weighted images were also acquired at several time points after injection (24 h and 7, 15, 30 and
60 days) for liver. A decrease in darkness of the liver was evident with increasing time for both CAs indicating
clearance from the liver Supplementary Figure 4. T2 values in liver have been calculated and plotted as a function
of the acquisition time in Figure 7, data for R values are shown in Supplementary Figure 5.
After the sharp decrease in both T2 and R values in liver observed at 2 h after injection, increasing time was
associated with an increase in T2 and R values which is expected as CA clearance from liver. Comparing the
pre-contrast values to post-contrast values in both CAs, a significant difference is observed in T2 values between
bioferrofluids and control (pre) until 30 days after injection, while in R there are significant differences only until
15 days after injection. In the case of Endorem, both T2 and R values show statistical significant differences to the
control (pre) until 15 days after injection.
Qualitative iron detection using Prussian blue assay
Prussian blue assays were carried out to detect free ferric ions in liver and kidney. Results showed that there is an
accumulation of both bioferrofluids and Endorem in liver after 2 h of injection, which is indicated by the presence
of blue dots in the tissue samples, as shown in Figure 8B & C.
In the case of Endorem, a high amount of iron was detected until 7 days after injection, as shown in Figure 8D
& F, and then the amount decreased after 15 days, as shown in Figure 8H. Endorem was not detected after 30 days
and above, as shown in Figure 8J & L. In the case of bioferrofluids, although the amount of iron seems to be less
to that of Endorem, it exists for a longer period. Iron was detected until 30 days after bioferrofluids injection, as
shown in Figure 8E, G, I & K. Bioferrofluids were not detected after 60 days of injection, as shown in Figure 8M.
Table 1 shows a perspective idea regarding ferric ion concentration in liver tissue after CA injection. Prussian blue
results confirmed the results obtained by MRI.
In the case of kidney, an accumulation of ferric ions was just detected in the period between 2 h and 15 days
after Endorem injection. However, in the case of bioferrofluids, ferric ions accumulate until 60 days after injection
(Supplementary Figure 6).
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Figure 8. Qualitative iron detection. Prussian blue assay
in mouse liver of non-injected mouse (A) and after 2 h
(B, C), 1 day (D, E), 7 days (F, G), 15 days (H, I), 30 days (J,
K) and 60 days (L, M) of Endorem R© (left panel) and
bioferrofluids (right panel) injection. Black arrows are
pointing ferric ions which appear as blue colored dots.
Scale bar 50 μm.
Table 1. A perspective idea about ferric ion concentration in liver of mice after contrast agent injection using Prussian
blue assay.
Time Endorem R© Bioferrofluids
0 - -
2 h +++ +
1 day +++ ++
7 days +++ +
15 days + +
30 days - +
60 days - -
In vivo toxicity studies
Both Endorem and bioferrofluids did not generate any notable histological lesions in liver at different time points
(2 h and 1, 7, 15, 30 and 60 days) after CA injection. Figure 9 is an example of the histopathological studies in
mouse liver after 7 days of CA injection. A thorough study on the bioferrofluids toxicity and their biodistribution
is in preparation and will be published elsewhere.
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Figure 9. In vivo toxicity study. Hematoxin and Eosin stain in liver of non-injected mouse (A) and after 7 days of bioferrofluids (B) and
Endorem R© (C) injection. Scale bar 25μm.
Discussion
Obtained results show that both bioferrofluids and commercial Endorem exhibit similar behavior in shortening T2
relaxation time, since an increase in the nanoparticles concentration is associated with a decrease in SI, as shown
in Supplementary Figure 1. The efficiency of T2 CAs depends on r2 more than on r1. It has been reported that the
higher the r2/r1 ratio the better the efficiency of a negative CA [31,32]. r1 and r2 relaxivities are dependent on the
nanoparticle size in a direct proportion relationship. The effect of nanoparticle size on the r1 and r2 relaxivities of the
here studied bioferrofluids as compared with Endorem has been investigated by Amiri et al. [27]. Therefore, it was
expected that r1 and r2 values for bioferrofluids (Dp = 13 nm) were higher than for Endorem (Dp = 6–9 nm). On
the contrary, bioferrofluids show lower values of r2 and r1 as compared with Endorem. Amiri’s results show that the
r2 value in bioferrofluids of Dp = 15 nm is higher than in the case of Endorem. Differences between Amiri’s and our
study are in the operating frequencies. The experiments here reported were carried out at a frequency of 200 MHz
(corresponding to 4.7 T clinical imager). Instead, Amiri et al. carried out their experiments at lower frequencies
(8.5, 21 and 63 MHz corresponding to about 0.2, 0.5 and 1.5 T clinical imagers, respectively). In their study it is
evident that r1 is size dependent at low frequencies (0.01–0.1 MHz); larger nanoparticle sizes have higher r1 values.
At higher frequencies (10–100 MHz), a decrease in r1 values was reported for all bioferrofluid samples, Endorem
showing higher r1 comparative values. This may explain the lower value of r1 obtained by our bioferrofluids as
compared with Endorem at 200 MHz. On the other hand, r2 was found to be frequency independent in the
frequency range between 4 and 80 MHz, with values corresponding to Endorem being somewhat lower than the
corresponding ones for particles of 15 nm and somewhat higher than those for particles of 10 nm. It seems that
this behavior extends to higher frequencies given the slightly lower values of r2 obtained by our bioferrofluids as
compared with Endorem at high frequency (200 MHz). The efficiency of a T2 contrast depends on its r2 relaxivity
as well as the r2/r1 ratio: the higher the ratio of r2/r1, the better the efficiency of a T2 CA [31,33]. The calculation
of the r2/r1 ratio for both bioferrofluids and Endorem shows that our bioferrofluids have a higher r2/r1 ratio than
Endorem and this could be an advantage of our bioferrofluid compared with commercial Endorem.
The bioferrofluids and Endorem efficiency as MRI CAs in steady-state condition was evaluated by acquiring
T2*-weighted images in brain before (pre-contrast) and during 2h post-contrast injection. While 2 h after injection
of Endorem the brain vasculature was still hypointense, see Figure 5C, in the case of the bioferrofluids R had
recovered to pre-injection values (Figure 5G & Supplementary Figure 2). This indicates a complete clearance of
bioferrofluids from the circulation at this time point. It is clear that the bioferrofluids have a half-life time in blood
shorter than Endorem. The fast clearance of the nanoparticles from the circulation could be by reticuloendothelial
system ‘opsonization’. Opsonization depends on several factors, such as nanoparticle size, charge, surface coating
and dose. Coating the nanoparticles with a hydrophilic polymer that reduces the non-specific binding of opsonin
proteins could reduce the opsonization effect. Thus, the magnetite core of Endorem is coated with dextran while
the bioferrofluids here studied are composed of maghemite cores coated with P4VP-g-PEGA. Several studies
show that the long blood circulation time is achieved by increasing the chain length of PEG [19–22]. The surface
of the nanoparticles in the P4VP-g-PEGA bioferrofluids is formed by 1/10 in weight of PEGA long chains
(MW = 1000) and 9/10 of PEGA short chains (MW = 200). Therefore, these short chains of PEG might not
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protect the nanoparticles from non-specific protein adsorption and subsequent opsonization, leading to short blood
circulation time. A study to identify protein corona formation is recommended. In addition to the surface coating,
the nanoparticle size plays a crucial role in nanoparticle opsonization; larger size nanoparticles are cleared faster
than smaller size ones. The hydrodynamic diameter of bioferrofluids is 163 nm, while for Endorem is 110 nm.
Therefore, the large size of bioferrofluids increases their chance for opsonization and clearance from the circulation.
Regarding rCBV maps, Endorem seems to contrast well the space arrangement of cerebral blood vessels, while the
bioferrofluids show a darker image (Figure 5D & H).
The dosage of iron administered in brain imaging in the present study may appear considerably high in
comparison with the clinical dosage of Endorem. It is to be considered that the dose of CA injected strongly depends
on the specific application. Iron-oxide nanoparticles are used in brain studies because they remain confined for
long time intervals in the vascular space, differently from small molecular weight CAs (e.g., Gd-DTPA) that are
rapidly cleared from blood. This property allows measurement of rCBV and its alterations due to pathologies or to
stimulations. High dosages of iron-oxide are administered in brain CBV studies to create a large contrast between
pre- and post-contrast images. In a recent review, Kim et al. [34]. advise 5–15 mgFe/kg to measure CBV.Wu et al. [35]
measured microvascular volume distribution in mice using a 30 mgFe/kg injection at 9.4 T and demonstrated that
CBV in the cerebral cortex is higher in transgenic APP mice, an experimental model of Alzheimer’s disease, than in
controls. CBV-weighted functional MRI (fMRI) has been extensively used in experimental fMRI [36,37]; thanks to
the increased sensitivity of CBV-weighted contrast compared with classical blood oxygen level-dependent (BOLD)
contrast. At 7 T, 15-20 mg Fe/kg ultrasmall superparamagnetic iron oxides improve functional contrast-to-noise
ratio (CNR) by 70% in rats compared with BOLD contrast [38]. Mandeville et al. [39] reported that CNR in CBV-
weighted fMRI with 28 mgFe/kg improved twofold compared with BOLD upon pharmacological stimulation
with cocaine. Even in humans, relatively high dosages of ultrasmall superparamagnetic iron oxides of 7 mgFe/kg
have been used in fMRI acquisitions [40].
MRI studies related to the accumulation of both CAs in liver 2 h after injection at a dose of 20 μmol Fe/kg
body weight indicated no significant difference between bioferrofluids and Endorem. Estimation for the iron
concentration in liver after 2 h post-contrast injection yields a similar concentration of 0.05 μM for both CAs.
The similarity between both CAs in the estimated accumulated iron concentration in liver tissues is consequent
with their similarity in decreasing the T2 and T2* values. Qualitative detection of iron using Prussian blue assay
shows a higher amount of iron in the liver of mice injected with Endorem than with bioferrofluids, as shown in
Figure 8B & C. There may be two explanations supporting these results. First, Prussian blue is not a sensitive
method; however, it confers optical perspective idea about the existence of ferric ion in liver. A second explanation
can be the presence of EndoremR© in Kupffer cells as agglomerates. However, our bioferrofluids are distributed in
Kupffer cells and hepatocytes.
The presence of CAs in liver was evaluated at several time points until 60 days post-injection. By increasing the
time a decrease in darkness of the liver was observed (Supplementary Figure 4), which indicates CA degradation
and clearance from liver tissue. Both T2 and R values show time dependence. T2 values between bioferrofluids and
control (pre) show a significant difference until 30 days after injection, while R values show significant difference
until 15 days after injection. In the case of Endorem, both T2 and R values show statistically significant difference
to the control until 15 days after injection. These results are confirmed by Prussian blue assay. Bioferrofluids are
observed as blue colored dots until 30 days post-injection (Figure 8K) and disappear at 60 days after injection
(Figure 8M), while Endorem is observed until 15 days after injection (Figure 8H) and absent at 30 and 60 days
after injection (Figure 8J & L). These results indicate that our bioferrofluids persist for a longer time than Endorem
in liver with no toxic effects observed in mice.
Prussian blue assay shows only few blue colored dots in kidney of mice injected with Endorem and bioferrofluids,
as shown in Supplementary Figure 6. Detected iron by Prussian blue does not confirm CAs accumulation in kidney,
as the source of iron in kidney (exogenous or endogenous) is unknown.
Bioferrofluids have advantages and disadvantages compared with Endorem. In brain studies, bioferrofluids
demonstrated less efficacy in decreasing brain signal and faster clearance from blood so Endorem is superior for
brain imaging in both first passage and steady state techniques. In liver imaging, the two CAs produced similar
efficacy, but bioferrofluids remained in liver for longer time intervals. The long-time permanence of CA in the liver
can be an advantage in the clinical settings allowing first the diagnosis of a liver pathology and then monitoring
after treatment without the need for a second injection [41]. Finally, bioferrofluids have transversal relaxivity smaller
or at most equal to Endorem but higher r2/r1 ratio that contributes to the efficiency of a T2 relaxing CA.
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Conclusion
Our bioferrofluid is a good T2 CA with a higher r2/r1 ratio than commercial Endorem. It has shorter blood
circulation time compared with Endorem and they are efficient reticuloendothelial system agents as their persistence
is observed in liver tissue. Our bioferrofluid persists in liver for longer period of time (up to 30 days post-injection)
than Endorem with no toxic effect observed in liver tissue. Moreover, our bioferrofluid has shown a much higher
magnetic heating power than Endorem [10], so it would be valuable for theranostics. Accumulation of CAs in
kidney was not clear and requires further studies to be confirmed. Studies pertaining to protein adsorption on the
nanoparticle surface ‘protein corona’ are recommended.
Future perspective
SPIONs are an attractive platform for biomedical applications. In recent years, we have been developing a mul-
tifunctional nanoplatform of polymer-based SPIONs, which can be functionalized with antibodies, drugs, etc.
Several studies were carried out to study the in vitro toxicity, ex vivo hematotoxicity, in vitro relaxivity and in vitro
magnetothermic responses. Obtained results from these studies make these nanoparticles as good candidates for
theranostics. The present study represents a complementary part of the previous studies. Here, we investigate the
diagnostic potential of our nanoparticles as T2 CA for MRI in vivo, their uptake and toxicity in liver. Studies of in
vivo toxicity, biodistribution, biodegradability and excretion will be carried out in the near future as unavoidable
studies required before considering access to clinical phases.
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Summary points
 Obtained results from previous in vitro cytotoxicity, ex vivo blood compatibility, relaxometry and
magnetothermal studies make these bioferrofluids a good candidate for theranostics.
 Bioferrofluids is a good T2 contrast agent with a higher r2/r1 ratio than commercial Endorem
R©.
 Bioferrofluids have shorter blood circulation time in comparison with Endorem.
 Bioferrofluid persists in liver for longer period of time (up to 30 days post-injection) than Endorem.
 Bioferrofluids have no toxic effect in mice liver.
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